Senti Bio Appoints Entrepreneurial Leader and Investor, Bryan Baum, to Board of Directors
SOUTH SAN FRANCISCO, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”),...
Clinical Trial
Generation Bio Announces 1-for-10 Reverse Stock Split
CAMBRIDGE, Mass., July 18, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company working to change what’s...
Trogenix Bolsters Clinical Research Team with Appointment of Atif Abbas as Chief Medical Officer and Carolyn Edwards as Vice President, Research & Development
Trogenix Bolsters Clinical Research Team with Appointment of Atif Abbas as Chief Medical Officer and Carolyn Edwards as Vice President,...
Zevra Therapeutics Announces MIPLYFFA® and OLPRUVA® Presentations at the Annual Meeting of the Southeastern Regional Genetics Group (SERGG)
CELEBRATION, Fla., July 18, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company...
Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for OCU410ST—Novel Modifier Gene Therapy Candidate for Stargardt Disease
MALVERN, Pa., July 18, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader...
ImCheck’s ICT01 Receives FDA Orphan Drug Designation for Treatment of Acute Myeloid Leukemia
ImCheck’s ICT01 Receives FDA Orphan Drug Designation for Treatment of Acute Myeloid Leukemia Clinical data showing unprecedented remission rates in...
Orion Group Half-Year Financial Report January–June 2025
ORION CORPORATION HALF-YEAR FINANCIAL REPORT 1–6/2025 18 JULY 2025 at 12:00 EEST Orion Group Half-Year Financial Report January–June 2025 April–June...
Trogenix Bolsters Clinical Research Team with Appointment of Atif Abbas as Chief Medical Officer and Carolyn Edwards as Vice President, Research & Development
Trogenix Bolsters Clinical Research Team with Appointment of Atif Abbas as Chief Medical Officer and Carolyn Edwards as Vice President,...
SAPU Bioscience Highlights Peer‑Reviewed Publication Linking TGFB2 to Survival in Younger Pancreatic Cancer Patients
Data supports further evaluation of investigational antisense OT‑101 (trabedersen) as a TGFB2‑targeted approach in pancreatic ductal adenocarcinoma. SAN DIEGO, Calif.,...
Successful Commercial Launch of Ryoncil®
Activity Report for Quarter Ended June 30, 2025 (Appendix 4C)NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO;...
Hemostemix Closing $3,000,000 Private Placement
Calgary, Alberta--(Newsfile Corp. - July 17, 2025) - Further to the June 26 and July 9th press releases announcing the...
Hemostemix Closing $3,000,000 Private Placement
Calgary, Alberta--(Newsfile Corp. - July 17, 2025) - Further to the June 26 and July 9th press releases announcing the...
UroMems Receives Clearance from the FDA and the French ANSM for Initiating Landmark Pivotal Clinical Study of UroActive® Smart Implant to Treat Male Stress Urinary Incontinence
IDE approval in both countries follows strong feasibility clinical results in France GRENOBLE, France and MINNEAPOLIS, July 17, 2025 /PRNewswire/...
Nearly 75% of Physicians Say Time-Consuming Clinical Trial Searches Delay Patient Treatment, New myTomorrows Report Reveals
Physicians believe AI could speed up clinical trial matching and enrollment, increasing patient access to relevant emerging treatments, according to...
Connect Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
SAN DIEGO, July 17, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a...
Fifty 1 Labs, Inc. (FITY) Sparks AI Breakthrough in Drug Repurposing: Subsidiary Fifty1 AI Labs Announces Strategic Partnership with Intent to Acquire BioSpark AI Technologies
SEATTLE, July 17, 2025 (GLOBE NEWSWIRE) -- via IBN -- Fifty1 AI Labs, LLC, an innovative subsidiary of Fifty 1...
Actuate Therapeutics Advances Clinical Program in Ewing Sarcoma After Positive Phase 1 Trial Demonstrates Complete and Partial Responses in Difficult-to-Treat Pediatric Sarcomas
- Announces Completion of Phase 1 Study of Elraglusib in Pediatric Patients - Prolonged and Durable Complete Responses (CRs) Observed...
Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer
Dr. Zuraw led clinical development of telitacicept across MG, Sjögren’s, SLE, and RA at RemeGen, resulting in multiple regulatory approvals...
BioNTech Announces Ryan Richardson to Step Down from the Management Board
MAINZ, Germany, July 17, 2025 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that Ryan...
Moleculin Engages Industry Veteran Adriano Treve to Explore Accelerated Strategic Partnerships
Moleculin Biotech, Inc. Adriano Treve 40+ year career at Roche founded on dedication to bringing new innovative medicines to patients...